Supernus Pharmaceuticals Retained Earnings (Accumulated Deficit) 2011-2024 | SUPN
Supernus Pharmaceuticals retained earnings (accumulated deficit) from 2011 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Supernus Pharmaceuticals Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$483 |
| 2022 |
$481 |
| 2021 |
$380 |
| 2020 |
$326 |
| 2019 |
$200 |
| 2018 |
$86 |
| 2017 |
$-27 |
| 2016 |
$-84 |
| 2015 |
$-176 |
| 2014 |
$-189 |
| 2013 |
$-179 |
| 2012 |
$-86 |
| 2011 |
$-40 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$541 |
| 2024-06-30 |
$503 |
| 2024-03-31 |
$483 |
| 2023-12-31 |
$483 |
| 2023-09-30 |
$481 |
| 2023-06-30 |
$497 |
| 2023-03-31 |
$498 |
| 2022-12-31 |
$481 |
| 2022-09-30 |
$456 |
| 2022-06-30 |
$454 |
| 2022-03-31 |
$446 |
| 2021-12-31 |
$380 |
| 2021-09-30 |
$377 |
| 2021-06-30 |
$356 |
| 2021-03-31 |
$332 |
| 2020-12-31 |
$326 |
| 2020-09-30 |
$296 |
| 2020-06-30 |
$256 |
| 2020-03-31 |
$221 |
| 2019-12-31 |
$200 |
| 2019-09-30 |
$166 |
| 2019-06-30 |
$138 |
| 2019-03-31 |
$105 |
| 2018-12-31 |
$86 |
| 2018-09-30 |
$61 |
| 2018-06-30 |
$33 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
$-27 |
| 2017-09-30 |
$-40 |
| 2017-06-30 |
$-56 |
| 2017-03-31 |
$-74 |
| 2016-12-31 |
$-84 |
| 2016-09-30 |
$-99 |
| 2016-06-30 |
$-160 |
| 2016-03-31 |
$-171 |
| 2015-12-31 |
$-176 |
| 2015-09-30 |
$-182 |
| 2015-06-30 |
$-186 |
| 2015-03-31 |
$-189 |
| 2014-12-31 |
$-189 |
| 2014-09-30 |
$-193 |
| 2014-06-30 |
$-191 |
| 2014-03-31 |
$-194 |
| 2013-12-31 |
$-179 |
| 2013-09-30 |
$-156 |
| 2013-06-30 |
$-132 |
| 2013-03-31 |
$-105 |
| 2012-12-31 |
$-86 |
| 2012-09-30 |
$-73 |
| 2012-06-30 |
$-59 |
| 2012-03-31 |
$-49 |
| 2011-12-31 |
$-40 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
